Phase II studies: Wrong doses, wrong patients?
- 1 October 1991
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (10) , 1198-1200
- https://doi.org/10.1016/0277-5379(91)90080-w
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990
- Carboplatin and ifosfamide in ovarian cancer phase II and III trialsCancer Chemotherapy and Pharmacology, 1990
- P-Glycoprotein expression in treated and untreated human breast cancerBritish Journal of Cancer, 1989
- Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trialsBritish Journal of Cancer, 1989
- First-line chemotherapy rechallenge after relapse in small cell lung cancerCancer Chemotherapy and Pharmacology, 1988
- Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1987
- Mitoxantrone (NSC-3O1739) in patients with advanced ovarian carcinomaAmerican Journal of Clinical Oncology, 1984
- Mitoxantrone in epithelial carcinoma of the ovaryAmerican Journal of Clinical Oncology, 1984
- Epipodophyllotoxin (VP16-213) in small cell carcinoma of the bronchus resistant to initial combination chemotherapyCancer Chemotherapy and Pharmacology, 1982